Product Description: Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement): 334-335./[2]Olga Ab, et al. Activity of huC242-DM4, an antibody-cytotoxic agent conjugate, used in combination with anti-neoplastic agents against gastric cancer cells in culture. Mol Cancer Ther (2007) 6 (11_Supplement): A127.
CAS Number: 868747-45-9
Molecular Weight: 150000 (average)
Compound Purity: 98.71
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin
English
Deutsch
